tiprankstipranks
Ascendis Pharma Gains UK Authorization for YORVIPATH
PremiumCompany AnnouncementsAscendis Pharma Gains UK Authorization for YORVIPATH
9d ago
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
PremiumPress Releases
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
9d ago
Ascendis Pharma announces MRHA approval of YORVIPATH in Great Britain
PremiumThe Fly
Ascendis Pharma announces MRHA approval of YORVIPATH in Great Britain
9d ago
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
PremiumPress ReleasesAscendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
2M ago
Ascendis Pharma A/S Is Worried About This – Should You Be Worried Too?
PremiumMarket News
Ascendis Pharma A/S Is Worried About This – Should You Be Worried Too?
3M ago
Ascendis Pharma price target raised to $225 from $207 at Wedbush
PremiumThe Fly
Ascendis Pharma price target raised to $225 from $207 at Wedbush
3M ago
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
PremiumPress ReleasesAscendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
3M ago
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
PremiumPress Releases
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
3M ago
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
PremiumPress Releases
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100